Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Alfred Novak Biography and Net Worth

Director of LivaNova

Alfred Novak has worked as a private investor since 2015. Prior to that, Mr. Novak served as President and CEO of Syntheon Cardiology LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve (2014 to 2015); Chair and CEO of OrbusNeich Medical Technology Company, Ltd., an interventional cardiology company (2010 to 2013); President and CEO of Novoste Corporation, an interventional cardiology company (2002 to 2006); founder of Syntheon, LLC, a company focused on minimally invasive medical devices for the gastroenterology and vascular markets (1998 to 2003); and President, CEO and a director of Biosense, Inc., an electrophysiology company (1996 to 1998). Prior to that time, Mr. Novak was Vice President and Chief Financial Officer of Cordis Corporation. Mr. Novak received a BS from the United States Merchant Marine Academy and an M.B.A. in Healthcare from The Wharton School of the University of Pennsylvania.

What is Alfred J. Novak's net worth?: The estimated net worth of Alfred J. Novak is at least $503,026.30 as of June 16th, 2020. Mr. Novak owns 10,570 shares of LivaNova stock worth more than $503,026 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Novak may own. Learn More about Alfred J. Novak's net worth.
How do I contact Alfred J. Novak?: The corporate mailing address for Mr. Novak and other LivaNova executives is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. LivaNova can also be reached via phone at 442033250660 and via email at [email protected]. Learn More on Alfred J. Novak's contact information.
Has Alfred J. Novak been buying or selling shares of LivaNova?: Alfred J. Novak has not been actively trading shares of LivaNova during the last ninety days. Most recently, Alfred J. Novak sold 644 shares of the business's stock in a transaction on Wednesday, November 10th. The shares were sold at an average price of $90.77, for a transaction totalling $58,455.88. Learn More on Alfred J. Novak's trading history.
Who are LivaNova's active insiders?: LivaNova's insider roster includes Marco Dolci (SVP), Damien McDonald (CEO), Daniel Moore (Director), and Alfred Novak (Director). Learn More on LivaNova's active insiders.
Are insiders buying or selling shares of LivaNova?: During the last year, insiders at the sold shares 2 times. They sold a total of 57,873 shares worth more than $3,467,346.03. The most recent insider tranaction occured on December, 11th when Director Francesco Bianchi sold 1,250 shares worth more than $63,737.50. Insiders at LivaNova own 0.3% of the company. Learn More about insider trades at LivaNova.
Information on this page was last updated on 12/11/2024.

Alfred J. Novak Insider Trading History at LivaNova

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/10/2021	Sell	644	$90.77	$58,455.88
6/16/2020	Buy	1,000	$46.71	$46,710.00	10,570
5/9/2019	Sell	1,300	$70.63	$91,819.00
12/11/2018	Sell	500	$97.16	$48,580.00
6/14/2018	Sell	1,000	$104.43	$104,430.00
5/9/2018	Sell	1,000	$84.02	$84,020.00
11/22/2017	Sell	2,000	$85.77	$171,540.00
5/22/2017	Sell	1,000	$58.49	$58,490.00	12,020
5/6/2016	Sell	4,000	$51.12	$204,480.00	13,020

Alfred J. Novak Buying and Selling Activity at LivaNova

LivaNova Company Overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $47.59

$47.03

$49.32

50 Day Range

MA: $51.60

$47.49

$53.82

2 Week Range

Now: $47.59

$43.15

$64.47

Volume

1,387,306 shs

Average Volume

612,641 shs

Market Capitalization

$2.58 billion

P/E Ratio

113.31

Dividend Yield

N/A

Beta

0.98

Most People Are Dead Wrong.

From Brownstone Research | Ad